Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study / Caocci, G., Mulas, O., Capodanno, I., Abruzzese, E., Iurlo, A., Luciano, L., Albano, F., Annunziata, M., Tiribelli, M., Bonifacio, M., Galimberti, S., Castagnetti, F., Sgherza, N., Stagno, F., Gozzini, A., Orlandi, E.M., Luzi, D., Binotto, G., Pregno, P., Fozza, C., et al.. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 10:6(2020), p. 66. [10.1038/s41408-020-0333-2]